What is Wakix - Pitolisant and what is it used for?
Rasagiline Mylan is a medicine used to treat adult patients with Parkinson's disease (a progressive brain disease causing tremor, slow movement and muscle stiffness).
Rasagiline Mylan can be used alone or as an add-on to levodopa (another medicine used in Parkinson's disease) in patients with fluctuations in their disease control. Fluctuations occur when the effects of the medicine wear off and symptoms return before the next dose. They are due to a reduction in the effect of levodopa, when the patient suddenly goes from “on” phases in which he is able to move, to “off” phases in which he has difficulty in movement.
Rasagiline Mylan is a 'generic medicine'. This means that Rasagiline Mylan is similar to a 'reference medicine' already authorized in the European Union (EU) called Azilect. For more information on generic medicines, see the questions and answers by clicking here.
Rasagiline Mylan contains the active substance rasagiline.
How is Wakix - Pitolisant used?
Rasagiline Mylan is available in tablet form (1 mg). The standard dose is one tablet once a day.
The medicine can only be obtained with a prescription.
How does Wakix - Pitolisant work?
The active substance in Rasagiline Mylan, rasagiline, is a monoamine oxidase B inhibitor. It blocks the enzyme monoamine oxidase type B which degrades a substance called dopamine in the brain. Dopamine is important for the control of movement and coordination. . In patients with Parkinson's disease there is a loss of the cells that produce dopamine and, therefore, a reduction in the amount of this substance present in the brain. Patients therefore lose the ability to control their movements reliably. Rasagiline Mylan reduces the symptoms of Parkinson's disease, such as stiffness and slowness of movement, by increasing dopamine levels in the areas of the brain that control movement and coordination.
What benefit has Wakix - Pitolisant shown during the studies?
Since Rasagiline Mylan is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Azilect. Two medicines are bioequivalent when they produce the same levels of the active substance in the body
What is the risk associated with Wakix - Pitolisant?
Because Rasagiline Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Why has Wakix - Pitolisant been approved?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Rasagiline Mylan has been shown to have comparable quality and to be bioequivalent to Azilect. Therefore, the CHMP considered that, as in the case of Azilect, the benefits outweigh the identified risks and recommended that Rasagiline Mylan be approved for use in the EU.
What measures are being taken to ensure the safe and effective use of Wakix - Pitolisant?
A risk management plan has been developed to ensure that Rasagiline Mylan is used as safely as possible. Based on this plan, safety information has been added to the summary of product characteristics and package leaflet for Rasagiline Mylan, including the appropriate precautions to be followed by healthcare professionals and patients.
More information about Wakix - Pitolisant
For the complete version of Rasagiline Mylan's EPAR, consult the Agency's website: ema.europa.eu/Find medicine / Human medicines / European public assessment reports. For more information about Rasagiline Mylan therapy, read the package leaflet (included with the EPAR) or contact your doctor or pharmacist. The full EPAR version of the reference medicine can also be found on the Agency's website.
The information on Wakix - Pitolisant published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
